Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0277571 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Francesc López Seguí und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Germans Trias i Pujol, Barcelona, Spain. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents, Sexual and Gender Minorities. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Pre-Exposure Prophylaxis (PrEP) for HIV prevention has been implemented in several countries. Previous literature has shown that its cost-effectiveness (and, under some specifications, cost-saving character) is dependent on the reduction in price due to generics, the time-horizon and its effectiveness. The intervention has never been studied in Catalonia after the approval of the PrEP, a territory with extensive implementation.
Methods
Economic evaluation of the implementation of HIV pre-exposition prophylaxis using administrative data from Men who have Sex with Men (MSM) who receive the treatment (at the generic price) compared with non-implementation. A deterministic compartmental model and a social perspective with a micro-costing approach over the time horizon 2022–2062 are used. A baseline 86% effectiveness of PrEP is assumed.
Results
Daily oral PrEP is found to be cost-saving: discounted savings in costs are attained after 16 years, and after 40 years they reach 81 million euros. In terms of health indicators, 10,322 additional discounted QALYs are generated by the intervention. Results are sensitive to sexual behavioral patterns among MSM, the price of PrEP (reduced if offered on-demand), its effectiveness and the discount rate.
Conclusions
The use and promotion of PrEP in Catalonia is predicted to result in substantial health and monetary benefits because of reductions in HIV infections. Short-term investments in the promotion of PrEP will result in important cost-savings in the long term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Germans Trias i Pujol, Barcelona, Spain.
- Centre de Recerca en Economia de la Salut, Barcelona, Spain.
- Fundació Lluita Contra les Infeccions, Barcelona, Spain.
- Research Group on Innovation, Health Economics and Digital Transformation (IGTP), Barcelona, Spain.
- AIDS Research Institute-IrsiCaixa, Barcelona, Spain.
- Projecte dels NOMS-Hispanosida, Barcelona, Spain.
ORCID-Profile: Francesc López Seguí
Zitieren
APA
López Seguí, F., Oyón Lerga, U., Laguna Marmol, L., Coll, P., Andreu, A., Meulbroek, M., López Casasnovas, G., Estrada Cuxart, O., Ara Rey, J., Quiñones, C., Pérez, F., Fernandez, J., Rivero, À., Ricou Ríos, L., & Clotet, B. (2023). Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona. PLOS ONE. https://doi.org/10.1371/journal.pone.0277571
Vancouver
López Seguí F, Oyón Lerga U, Laguna Marmol L, Coll P, Andreu A, Meulbroek M, et al. Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona. PLOS ONE. 2023. doi:10.1371/journal.pone.0277571
BibTeX
@article{LpezSegu2023,
author = {López Seguí, Francesc and Oyón Lerga, Unai and Laguna Marmol, Laura and Coll, Pep and Andreu, Angels and Meulbroek, Michael and López Casasnovas, Guillem and Estrada Cuxart, Oriol and Ara Rey, Jordi and Quiñones, Carles and Pérez, Fèlix and Fernandez, Javier and Rivero, Àngel and Ricou Ríos, Laura and Clotet, Bonaventura},
title = {Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0277571}
}
EUVIMED